{"id":"other-standard-therapy-for-adhd","safety":{"commonSideEffects":[{"rate":null,"effect":"Insomnia or sleep disturbance"},{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nervousness or anxiety"},{"rate":null,"effect":"Increased heart rate or blood pressure"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Standard ADHD therapies typically work by enhancing catecholamine neurotransmission in brain regions responsible for attention, impulse control, and executive function. Stimulants (e.g., amphetamines, methylphenidate) increase dopamine and norepinephrine release, while non-stimulants (e.g., atomoxetine, guanfacine) may work through selective reuptake inhibition or alpha-2 agonism. Without a specific drug name or code, the exact mechanism cannot be definitively stated.","oneSentence":"This represents a standard ADHD therapy from Eli Lilly, likely a stimulant or non-stimulant that increases dopamine and/or norepinephrine activity in the central nervous system to improve attention and reduce hyperactivity.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:24:57.205Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention-Deficit/Hyperactivity Disorder (ADHD)"}]},"trialDetails":[{"nctId":"NCT06229600","phase":"","title":"REspiratory reHABilitation and PSYchiatric Comorbidities","status":"COMPLETED","sponsor":"Istituti Clinici Scientifici Maugeri SpA","startDate":"2024-01-02","conditions":"Respiratory Disease","enrollment":994},{"nctId":"NCT05918991","phase":"NA","title":"Interventions for English Language Learners At-Risk for ADHD","status":"RECRUITING","sponsor":"Florida International University","startDate":"2022-05-18","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":300},{"nctId":"NCT06863025","phase":"NA","title":"Effects of Neurofeedback Training on Attentional Deficits in Patients With Acquired Brain Injury","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hospitales Nisa","startDate":"2024-10-01","conditions":"Brain Injuries, Attention Disorder","enrollment":30},{"nctId":"NCT04737512","phase":"EARLY_PHASE1","title":"Mindfulness-Based ADHD Treatment for Children: a Feasibility Study","status":"COMPLETED","sponsor":"Yale University","startDate":"2021-02-01","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":68},{"nctId":"NCT02900144","phase":"NA","title":"Modified Comprehensive Behavioral Intervention for Tics (M_CBIT)","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2016-09","conditions":"Tourette Syndrome, ADHD","enrollment":17},{"nctId":"NCT04732572","phase":"NA","title":"Brain Tissue Integrity and Autonomic Function Alterations in Childhood OSA and ADHD, and After Adenotonsillectomy.","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2020-08-01","conditions":"Attention-deficit/Hyperactivity Disorder, Autonomic Nervous System Imbalance, Obstructive Sleep Apnea of Child","enrollment":100},{"nctId":"NCT03023644","phase":"NA","title":"Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2017-02-21","conditions":"Congenital Heart Defect, Executive Function, Children","enrollment":106},{"nctId":"NCT02759263","phase":"NA","title":"Improving Neurodevelopment in Adolescents With Congenital Heart Disease","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2016-06","conditions":"Congenital Heart Disease, Neurodevelopment, Executive Function","enrollment":60},{"nctId":"NCT02906501","phase":"","title":"Effect of Risperidone on Cognitive Functions in Adolescents With ADHD and Behavioral Disturbances","status":"UNKNOWN","sponsor":"Shalvata Mental Health Center","startDate":"2016-09","conditions":"ADHD","enrollment":45},{"nctId":"NCT02071186","phase":"NA","title":"The Effect of Non-pharmacological Novel Cognitive Interventions on Motor-Cognitive Function in Children With ADHD","status":"UNKNOWN","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2014-03","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":60},{"nctId":"NCT00447278","phase":"PHASE3","title":"A Study Comparing the Effect of Atomoxetine Versus Other Standard Care Therapy on the Long Term Functioning in Attention-Deficit/Hyperactivity Disorder (ADHD) Children and Adolescents","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2007-03","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":399}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Other standard therapy for ADHD","genericName":"Other standard therapy for ADHD","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This represents a standard ADHD therapy from Eli Lilly, likely a stimulant or non-stimulant that increases dopamine and/or norepinephrine activity in the central nervous system to improve attention and reduce hyperactivity. Used for Attention-Deficit/Hyperactivity Disorder (ADHD).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}